Ardelyx, Inc. ARDX R2KR3KPHARMA

Q: What is the current share price of Ardelyx, Inc. (ARDX)?

As of 2026-09-07 16:24 PDT, Ardelyx, Inc. (ARDX) trades at $3.78 on NasdaqGM. Its 52-week range is $3.71 to $7.99.

Q: What is the market capitalisation of ARDX?

Ardelyx, Inc. (ARDX) has a market capitalisation of $933.77M on NasdaqGM.

Q: What is the P/E ratio of ARDX?

ARDX trades at a trailing price-to-earnings (P/E) ratio of -15.75. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 5.86.

Q: What is the return on equity (ROE) of ARDX?

ARDX has a return on equity (ROE) of -39.46%. Its return on capital employed (ROCE) is -9.92%.

Q: Is ARDX a good stock to buy?

This page provides a data-driven analysis of Ardelyx, Inc. (ARDX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.ardelyx.com

Company Profile ↓

$3.78

-34.26% 1Y

Mkt Cap$933.77M

P/E-15.75

P/B5.86

52W High$7.99

52W Low$3.71

Book Value$0.68

EPS (TTM)$-0.24

Company Overview

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 48.1% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $407.32M (+22.1% YoY); net profit $-61.60M.
Trailing 12 Months Year-on-year growth — revenue +27.5%.
5-Year Trend Long-term compounding — revenue CAGR 48.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	48.12%
1 Year:	27.50%

Stock Price Performance

1 Year:	-34.26%
6 Months:	-38.93%
3 Months:	-32.01%
1 Month:	-22.38%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 2% of range

$3.71 $7.99

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)32.34 · Neutral

Price Performance

1M-22.38%

3M-32.01%

6M-38.93%

1Y-34.26%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 48.1% over 5 years.
Generates positive free cash flow.

CONS

Trading 52.7% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-15.75

Industry PE

25.17

Forward P/E

7.03

PEG Ratio

Book Value

$0.68

Price to Book

5.86

P/S

2.31

EV/EBITDA

-35.22

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

48.12%

Profit 5Y

Revenue (YoY)

27.50%

Earnings (YoY)

Profitability & Returns

ROCE

-9.92%

ROE

-39.46%

ROA

-5.11%

Profit Margin

-13.58%

Op Margin

-34.71%

Gross Margin

74.56%

EPS (Latest Qtr)

$-0.07

EPS (TTM)

$-0.24

Balance Sheet & Liquidity

Debt/Equity

1.58

Quick Ratio

2.93

Current Ratio

3.48

Debt

$234.13M

Total Assets

$575.89M

Current Assets

$381.87M

Working Capital

$293.71M

Ownership

Promoter Holding

3.17%

Chg in Prom Hold

-0.06%

FII / Inst Holding

73.31%

Chg in FII Hold

-0.02%

Financial Snapshot

Enterprise Value

$933.77M

Total Revenue (TTM)

$427.68M

EBITDA

$-34.05M

Free Cash Flow

$86.38K

Operating Cash Flow

$-36.26M

Shares Outstanding

247.03M

Gross Margin

74.56%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ARDX Ardelyx, Inc. R2KR3KPHARMA	3.78	-15.75	$933.77M	0.00%	-9.92%	-39.46%	48.12%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	-	-	-	2.32M	30.00K	172.00K	85.00K	-	18.00K	3.01M	2.25M	1.21M	1.84M	2.71M	1.81M	6.58M	1.31M	1.17M	468.00K	2.53M	4.99M	11.37M	22.33M	56.39M	46.02M	73.22M	98.24M	74.11M	97.66M	110.33M	125.22M	94.47M	120.88M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12.30M	12.40M	3.98M	10.85M	4.81M	-
Gross Profit	-	-	-	-	-	-	-	-	-	33.60M	1.86M	30.00K	170.00K	85.00K	-	18.00K	2.41M	2.25M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	61.81M	85.26M	106.35M	114.37M	89.66M	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	98.16M	99.65M	101.68M	109.27M	122.45M	-
Operating Income	-18.08M	-	-23.53M	-28.69M	-29.20M	-	-28.43M	-26.42M	-21.23M	-	-17.68M	-22.15M	-23.73M	-	-25.50M	-24.83M	-22.09M	-	-21.77M	-24.21M	-17.16M	-	-32.01M	-44.83M	-42.24M	-27.81M	-26.21M	-21.88M	-26.06M	-16.62M	7.40M	-24.68M	-13.63M	2.23M	-36.35M	-14.39M	4.67M	5.10M	-32.79M	-12.43M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-33.42M	-11.87M	8.02M	8.10M	-29.77M	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.26M	6.58M	7.98M	7.58M	6.92M	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-40.28M	-19.08M	-867.00K	-400.00K	-37.60M	-
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	859.00K	1.00K	102.00K	7.00K	8.00K	-
Net Income	-18.13M	-17.00M	-23.47M	-28.61M	-29.03M	-31.28M	-28.01M	-25.72M	-20.72M	10.11M	-17.02M	-22.29M	-24.13M	-27.86M	-26.14M	-25.47M	-23.54M	-19.79M	-22.37M	-24.96M	-18.11M	-28.88M	-33.16M	-45.19M	-43.59M	-28.07M	-26.94M	-22.89M	-26.77M	-17.12M	6.63M	-26.52M	-16.45M	-809.00K	-41.14M	-19.08M	-969.00K	-407.00K	-37.60M	-16.72M
Diluted EPS	-0.70	-0.65	-	-0.83	-	-	-0.59	-0.54	-0.44	0.21	-	-	-	-	-	-	-	-	-0.25	-0.28	-0.20	-	-0.34	-0.45	-0.42	-0.21	-0.19	-0.14	-0.13	-0.08	0.03	-0.11	-0.07	0.00	-0.17	-0.08	0.00	0.00	-0.15	-0.07
R&D Expense	14.71M	-	19.25M	23.84M	24.86M	-	22.39M	20.57M	15.37M	-	13.35M	16.05M	17.94M	-	20.38M	19.48M	17.58M	-	15.84M	18.86M	12.24M	-	20.46M	26.02M	23.70M	8.85M	9.74M	7.47M	9.09M	8.28M	8.64M	10.58M	12.76M	15.31M	14.94M	15.67M	18.07M	-	20.19M	26.10M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	5.41M	28.93M	31.62M	24.03M	-	42.00M	2.61M	5.28M	7.57M	-	52.16M	124.46M	333.62M	407.32M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	4.12M	17.80M	50.56M	39.54M
Gross Profit	-	-	-	24.03M	-	33.60M	2.14M	4.68M	-	-	48.04M	106.66M	283.06M	367.78M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	111.80M	169.94M	311.01M	408.76M
Operating Income	-8.80M	-2.87M	-1.56M	-29.39M	-112.89M	-65.11M	-90.95M	-91.26M	-90.78M	-	-63.76M	-63.28M	-27.95M	-40.98M
EBITDA	-	-	-	-	-	-	-	-	-	-	-60.98M	-55.35M	-16.71M	-29.17M
Interest Expense	-	-	-	-	-	-	-	-	-	-	5.07M	8.87M	20.09M	28.40M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-67.20M	-65.52M	-38.87M	-60.63M
Tax Provision	-	-	-	-	-	-	-	-	-	-	8.00K	547.00K	266.00K	969.00K
Net Income	-9.79M	-6.56M	-3.21M	-29.62M	-112.39M	-64.34M	-91.30M	-94.94M	-94.31M	-	-67.21M	-66.07M	-39.14M	-61.60M
Diluted EPS	-	-	-	-	-	-	-	-1.47	-1.05	-	-0.42	-0.30	-0.17	-0.26
R&D Expense	10.18M	28.09M	25.90M	39.88M	94.16M	75.48M	69.37M	71.68M	65.05M	91.14M	35.20M	35.54M	52.32M	71.53M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Jan 2018	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	42.90M	113.41M	116.95M	213.13M	157.90M	-	183.33M	259.78M	201.56M	-	190.07M	297.58M	435.75M	501.60M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	153.60M	246.11M	356.45M	382.32M
Cash & Equivalents	10.78M	32.90M	34.44M	107.29M	107.00M	74.60M	75.38M	-	78.77M	181.13M	91.03M	-	96.14M	21.47M	64.93M	68.00M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	3.28M	12.45M	21.17M	17.73M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	7.73M	22.03M	57.70M	71.85M
Total Liabilities	-	-	50.23M	52.73M	8.04M	19.98M	18.59M	-	67.52M	73.13M	75.45M	-	91.74M	130.76M	262.46M	334.65M
Current Liabilities	-	-	17.14M	21.54M	7.72M	19.20M	17.87M	1.00M	17.73M	22.22M	28.42M	-	65.60M	50.39M	77.83M	88.61M
Long Term Debt	-	-	-	-	-	-	-	-	51.98M	50.01M	50.79M	-	-	49.82M	150.85M	202.83M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	36.46M	55.98M	153.44M	207.95M
Total Equity	-48.26M	-57.39M	-63.48M	60.68M	108.90M	193.15M	139.31M	-	115.81M	186.66M	126.11M	-	98.33M	166.82M	173.29M	166.95M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	198.58M	232.45M	238.02M	244.35M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-71.84M	-92.53M	-65.19M	-70.27M	-76.48M	-81.44M	-	-70.04M	-89.72M	-44.81M	-42.48M
Investing Cash Flow	-	-	-	-3.45M	-131.08M	65.29M	-29.89M	23.37M	-31.44M	-	18.41M	-131.25M	-18.32M	-8.96M
Financing Cash Flow	-	-	-	75.01M	191.20M	685.00K	103.55M	155.48M	22.78M	-	75.34M	146.29M	106.59M	54.51M
Capital Expenditure	-128.00K	-278.00K	-1.86M	-3.45M	-4.87M	-2.35M	-311.00K	-325.00K	-324.00K	-	-55.00K	-344.00K	-1.01M	-1.49M
Free Cash Flow	-	-	-	-75.29M	-97.40M	-67.55M	-70.58M	-76.81M	-81.76M	-	-70.10M	-90.06M	-45.82M	-43.98M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	23.71M	-74.67M	43.46M	3.07M
Share Buybacks	20.00K	2.00K	2.00K	-	-	-	-	-	-	-	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	100.0%	-	80.0%	82.1%	88.6%	-	-	92.1%	85.7%	84.8%	90.3%
Operating Margin %	-162.8%	-9.9%	-4.9%	-122.3%	-	-155.0%	-3,488.6%	-1,728.1%	-1,199.0%	-	-122.2%	-50.8%	-8.4%	-10.1%
Net Margin %	-180.9%	-22.7%	-10.2%	-123.3%	-	-153.2%	-3,502.0%	-1,797.8%	-1,245.7%	-	-128.9%	-53.1%	-11.7%	-15.1%
ROE %	17.0%	10.3%	-5.3%	-27.2%	-58.2%	-46.2%	-78.8%	-50.9%	-74.8%	-	-68.3%	-39.6%	-22.6%	-36.9%
ROCE %	-	-11.1%	-1.7%	-26.9%	-58.2%	-46.5%	-54.9%	-38.4%	-52.4%	-	-51.2%	-25.6%	-7.8%	-9.9%

Shareholding Pattern

Insiders

3.17%

Institutions

73.31%

Public Float

75.71%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	9.43%	23.50M	$89.55M
2	Rubric Capital Management LP	6.50%	16.20M	$61.73M
3	Millennium Management Llc	5.58%	13.90M	$52.96M
4	State Street Corporation	5.36%	13.36M	$50.89M
5	Vanguard Capital Management LLC	4.20%	10.47M	$39.90M
6	Nomura Asset Management International Inc	3.83%	9.55M	$36.37M
7	Vanguard Portfolio Management LLC	3.22%	8.03M	$30.58M
8	Geode Capital Management, LLC	2.57%	6.40M	$24.39M
9	Jupiter Topco LLC	2.13%	5.30M	$20.20M
10	Two Sigma Investments, LP	2.09%	5.21M	$19.85M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ARDX

Google News Sun, 06 Sep 2026

ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? - Stocktwits

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxPOTJTOHBTN0t5TlNjb1E2OUdHczdLb3FuNF83bEtmNXNUSjVHOHcwZDFxelphWlZLTi1kUXFLSUpDNmVLQ3B2UnpNOExHOW43STF4QUlpM040LXpFTEVyUU90Ui0wdWNIMkxzMXN5UnBIbXAwTnRfNEVDSUZUYlZWYjdpNEtWRk0xc3FnXz…

Google News Sat, 05 Sep 2026

Ardelyx Stock Price Forecast. Should You Buy ARDX? - StockInvest.us

<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE5BX1FGMFBDMncwdGR3WkZyRFZGYk5QZDI5TXljLWVWc0x1MHRzR3lJY2lwOXFCRUJiX1ZqdGg0b0RLMXJIRlJhZQ?oc=5" target="_blank">Ardelyx Stock Price Forecast. Should You Buy ARDX?</a>  <fo…

Google News Sat, 05 Sep 2026

ARDX Stock Tumbles As Xphozah Loses Final Medicare Reimbursement Battle - Stocktwits

<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxQS0ZGMUJoTy1xOFluZlNxazR1eDJQNjA0bVVoYy1Hb194U25scUdURXFFcTBPM280WER2TEJXdTBjaldHVkhXa0kxWW9KTDFjaG1lTXQ4NjQyQWZNLWN1STBMU0taYkFEal9LOUVwMlRZZlkxX1UxMDRZXzdPOWRIUXdPQ3lKUTR4dlVjV0…

Google News Fri, 12 Jun 2026

Ardelyx (ARDX) Stock Valuation Check After Recent Share Price Volatility - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNSUhWcHdNNlBadm52MTdVV2U2djFOczNDbWdUQ1JiNVFFc1dWSXdkd2E5NXQ3S0V1aDllZXcxRUxvX0ZncGZqSXlOQmIwNEE1dXhFZGJhLXhmRld5c2NrZndSZGt5NmM5dXJLclh4YW10Ql9pZVd2a2R6UjFnWDRRQzVieThSang2RUR6bF…

Google News hu, 13 Aug 2026

Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX) - PR Newswire

<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxQNXBRaTdoakZjOGJmVk01eVZ0MHhFNDZHRnlFWl91N0dNeXpXcDFFbHE4cklIRXBqQVhZUlkwV29TUWh4bE14LTdaM2hFYnJEamNmZk1aWW1JbHVBNlFWZWRZNlRaSlhlVUNIUXRTUVBRWVBnbjNZSDdYOXNLcTQyMFpROFZrcU5TNnAwTD…

Google News Fri, 21 Aug 2026

Ardelyx (NASDAQ: ARDX) exec plans 10,500-share RSU tax sale - Stock Titan

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQVTNoMTBSekMzSDdKTFFBSGtISHkwWWJBajNfUFlhbEdKWG1ELW9pOTRyWHQ2VWZoUkJxNDZ3RWRhOGgzZ3BQU3VnMTNIQU1HcGh4VzV4Q3UwVXg3N0d2am1xNmJuelVQbjhfR2Z5RUNNRzJtQTdjeEdySmVGbVYwNkNJalM1VUl3US1VdF…

ARDX — Frequently Asked Questions

What is the current share price of Ardelyx, Inc. (ARDX)?

As of 2026-09-07 16:24 PDT, Ardelyx, Inc. (ARDX) trades at $3.78 on NasdaqGM. Its 52-week range is $3.71 to $7.99.

What is the market capitalisation of ARDX?

Ardelyx, Inc. (ARDX) has a market capitalisation of $933.77M on NasdaqGM.

What is the P/E ratio of ARDX?

ARDX trades at a trailing price-to-earnings (P/E) ratio of -15.75. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 5.86.

What is the return on equity (ROE) of ARDX?

ARDX has a return on equity (ROE) of -39.46%. Its return on capital employed (ROCE) is -9.92%.

Is ARDX a good stock to buy?

This page provides a data-driven analysis of Ardelyx, Inc. (ARDX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Ardelyx, Inc. ARDX R2KR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? - Stocktwits

Ardelyx Stock Price Forecast. Should You Buy ARDX? - StockInvest.us

ARDX Stock Tumbles As Xphozah Loses Final Medicare Reimbursement Battle - Stocktwits

Ardelyx (ARDX) Stock Valuation Check After Recent Share Price Volatility - Yahoo Finance

Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX) - PR Newswire

Ardelyx (NASDAQ: ARDX) exec plans 10,500-share RSU tax sale - Stock Titan

ARDX — Frequently Asked Questions

What is the current share price of Ardelyx, Inc. (ARDX)?

What is the market capitalisation of ARDX?

What is the P/E ratio of ARDX?

What is the return on equity (ROE) of ARDX?

Is ARDX a good stock to buy?

Explore More